

Psychedelic Research



We have specialised research facilities for psychedelic testing including overnight capabilities.





Many of our research staff are fully trained in conducting psychedelic studies.



We are experienced in a number of psychedelic and dissociative drugs.

Our expertise

- Delivery of studies with complex designs and outcomes.
- Manufacturing (fully certified MIA (IMP) MHRA facility) and distribution of all classes of controlled substances with shipment globally (same day within the UK). MAC has 8 facilities with Schedule 1 licences.
- Expertise in different therapy areas including Major Depressive Disorder (MDD), Post-Traumatic Stress Disorder (PTSD), Treatment Resistant Depression (TRD), AND Generalised Anxiety Disorder (GAD). In addition, we have extensive experience in conducting studies in psychedelic naïve and non-naïve healthy volunteers.
- Set and Setting is critical, all of our clinics provide an environment that is secure, safe, and relaxing.
 - Private rooms aligned with psychedelic/hallucinogenic research to minimise acute psychological distress.
 - Our psychiatrists, therapist and facilitators oversee psychedelic treatments and monitor patients for psychological distress throughout the experience.





Psychedelic Studies

WE HAVE CONDUCTED **14** PSYCHEDELIC & DISSOCIATIVE DRUG STUDIES

We have experience in:

- ✓ **Ibogaine**
- ✓ **LSD**
- ✓ **Psilocybin**
- ✓ **D3 analogue of Psilocybin**
- ✓ **DMT/D3 DMT**
- ✓ **R-MDMA**
- ✓ **IV Psilocin**
- ✓ **NMDAR antagonist ketamine (dissociative)**


We are the first company to

- Dose Ibogaine in a clinical environment in the UK
- Dose 50mg Psilocybin
- Dose Deuterated DMT (IV/IM)



CNS studies

Our experience in psychedelic research is complemented by our rich history and expertise in conducting CNS studies



Rater Capabilities and Experience

Safety Assessments

CSSRS/BDS/S-STS

Semi-structured Interviews/Efficacy Assessments/Global and Clinical Outcome Assessments

MADRS/HAM-A/HAM-D/MMSE

Cognitive Battery/PANSS/CDR

CGI/CGI-S

Hachinski Ischaemia

Diagnostic assessments

MINI/SCID/NPI

Complex neuropsychiatric scales

YBOCS/BABS/CAPS-5



Psychedelic Scales including Pharmacodynamics (PD)

- Drug Effects VAS (Visual Analog Scale)/SDI (Subjective Drug Intensity)/ Intensity Rating Visual Analogue Scale (IRVAS)
- 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC)
- Patient Education Session Manual (PESM)
- Mystical Experience Questionnaire (MEQ30)
- Polysomnography (PSG)
- Clinician-Administered Dissociative Symptoms Scale (CADSS)
- Profile of Mood States (POMS)
- Bond-Lader VAS (Mood Rating Scale)
- Drug Effects Questionnaire (DEQ)
- Addiction Research Center Inventory-49 (ARCI-49 item Brief Scale)
- Positive and Negative Symptom Scale - Positive Scale (PANSS)
- Challenging Experience Questionnaire (CEQ)
- Blinding Integrity Questionnaire (BIQ)
- Scale for the Assessment and Rating of Ataxia (SARA)
- Ego Dissolution Inventory (EDI)
- Challenging Experience Questionnaire (CEQ)
- Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop)
- Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop)
- Objective Opiate Withdrawal Scale of Handelsman (OOWS-Handelsman)
- Drug History Questionnaire (DHQ)
- Addiction Severity Index (ASI)
- Heroin Craving Questionnaire - Short Form 14 (HCQ-SF-14)
- Strassman Hallucinogen Rating Scale (HRS)
- Patient Elicitation Narrative of Ibogaine, and Prochaska Stages of Change (SOC)
- Spielberger's State-Trait Anxiety Inventory Trait Subscale (STAI-T)
- Warwick-Edinburgh Mental Well being Scale (WEMWBS)
- Post-treatment Changes Scale (PTCS)
- Psychedelic Predictor Scale (PPS)
- Dysfunctional Attitude Scale (DAS)
- Ruminative Responses Scale (RRS)
- Social Connectedness Scale - Revised (SCC-R)
- Psychological Insight Scale (PIS)
- Emotional Breakthrough Inventory (EBI)
- Ecological momentary assessments (EMAs)/Face emotion recognition task (FERT)/ Reward functioning

Our Medical and Scientific Experts



Dr Aliya Asher
Chief Medical Officer



Dr Shoona Vincent
VP, Clinical Science



Dr David Gregory
Psychiatrist

Our people are one of our key strengths, equipped with a diverse range of experience and skill-sets. Our experts provide deep knowledge and understanding of conducting psychedelic research.

We have:

- **Psychiatrists with experience in psychedelics**
- **In-house psychologist**
- **Attendants/Facilitators/Dose Session Monitors**
- **Psychotherapists & dedicated Clinical Rating Specialists**
- **Registered nursing staff**
- **Assistant Psychologists/Psychedelic Attendants**



Our specialist team treat participants with compassion and empathy with the ability to reduce anxiety and distress.



We provide training & support programs both nationally and on a global scale


Case Study

MDD population treated with an oral psychedelic

Conducted at Psychedelic Centre of Excellence in Liverpool

Study Outcomes

- 57 participants screened, 17 randomised
- This study saw a huge response in participants with many people willing to travel significant distances to take part. This demonstrates that national interest in psychedelics within the UK is fast approaching the same scale as the US.



Participant Motivations

Healthy Volunteers

- Monetary incentive
- Support development of new treatments
- Curious about psychedelics

Patients

- Support development of new treatments
- Open to exploring treatment through psychedelics

MAC Clinical Research

- ✓ Over 30 years' experience in conducting clinical studies
- ✓ Full-service CRO with global reach
- ✓ 10 fully-owned research facilities in the UK
- ✓ Experts in healthy volunteer and patient recruitment



5-year summary

120+

SPONSORS

250+

STUDIES

50+

INDICATIONS

20+

FIH STUDIES

Our Services



CLINICAL RESEARCH SERVICES

Project Management

Clinical Operations

Site Monitoring
Site Management
Trial Feasibility

Pharmacovigilance

Regulatory Affairs

Biometrics

EDC
Data Management
SAS Programming
Biostatistics
Medical Writing

Vendor Management

Randomization and Trial Supply Management

Digital Solutions

Electronic Patient-Reported Outcomes (ePRO)
eConsent

Medical Monitoring



SITE & PATIENT SERVICES

Participant Recruitment

Participant Retention

Global Investigator Sites

Network of Fully-Owned Investigator Sites

Sleep Laboratory
Early Phase Unit
Psychedelic Testing Suites
Phase I - IV Research Facilities
Memory Assessment Research Centre



SCIENTIFIC SOLUTIONS

Human Models of Disease

Scientific and Endpoint Assessments

Cardiovascular Assessments
Cognitive and Neuropsychological Assessments

Dermatology Assessments

Imaging Assessments

Neurophysiology Assessments

Pain Assessments

Other Assessments

Rare diseases

Sleep Assessments

Psychedelics

Training



PHARMACEUTICAL SERVICES

GMP Manufacturing

In-House Pharmacy

Global Clinical Supplies

QP Release

IMP Management & Distribution

Controlled Drug Services

Laboratory Services

Clinical Pathology
Bioanalytical Services



STRATEGIC CONSULTANCY

Therapeutic Area Expertise & Study Development

Scientific Solutions & Pharmacodynamics

Clinical Science & Development

Medical Strategy, Input & Expertise

Statistical Analysis, Planning & Advice

Medical Writing

Laboratory Study Design, Methods & Conduct

Follow us on social



Visit macplc.com for more information